Monoclonal gammapathies in patients undergoing immunosuppressive treatment after renal transplantation. 1985

J Radl, and R M Valentijn, and J J Haaijman, and L C Paul

The frequency of monoclonal gammapathies (MG) and their possible origin were investigated in renal graft recipients undergoing immunosuppressive treatment. In a cross-sectional study, homogeneous immunoglobulins were found in 30% of the patients investigated. This incidence was 10-times higher than that in a control group of patients with chronic renal failure on dialysis treatment. The increase in the frequency of homogeneous immunoglobulins in the renal transplant recipients was related to the age of the patients but not to the duration of the immunosuppressive treatment. A longitudinal study in 55 patients demonstrated that most of the MG reflected transient B-cell monoclonal proliferations, probably due to an immunodeficiency; however, the incidence of benign and malignant B-cell neoplasias seemed also to be unusually high. These findings indicate that the immunosuppressive treatment enhances and accelerates an immunodeficiency which develops spontaneously with aging of the immune system; it also may contribute to the development of other age-related, both benign and malignant monoclonal B-cell proliferative disorders.

UI MeSH Term Description Entries
D007126 Immunoglobulin Allotypes Allelic variants of the immunoglobulin light chains (IMMUNOGLOBULIN LIGHT CHAINS) or heavy chains (IMMUNOGLOBULIN HEAVY CHAINS) encoded by ALLELES of IMMUNOGLOBULIN GENES. Allotypes, Immunoglobulin,Allotypic Antibodies,Antibodies, Allotypic,Ig Allotypes,Allotype, Ig,Allotype, Immunoglobulin,Allotypes, Ig,Allotypic Antibody,Antibody, Allotypic,Ig Allotype,Immunoglobulin Allotype
D007147 Immunoglobulin Light Chains Polypeptide chains, consisting of 211 to 217 amino acid residues and having a molecular weight of approximately 22 kDa. There are two major types of light chains, kappa and lambda. Two Ig light chains and two Ig heavy chains (IMMUNOGLOBULIN HEAVY CHAINS) make one immunoglobulin molecule. Ig Light Chains,Immunoglobulins, Light-Chain,Immunoglobulin Light Chain,Immunoglobulin Light-Chain,Light-Chain Immunoglobulins,Chains, Ig Light,Chains, Immunoglobulin Light,Immunoglobulins, Light Chain,Light Chain Immunoglobulins,Light Chain, Immunoglobulin,Light Chains, Ig,Light Chains, Immunoglobulin,Light-Chain, Immunoglobulin
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010265 Paraproteinemias A group of related diseases characterized by an unbalanced or disproportionate proliferation of immunoglobulin-producing cells, usually from a single clone. These cells frequently secrete a structurally homogeneous immunoglobulin (M-component) and/or an abnormal immunoglobulin. Gammapathy, Monoclonal,Gammopathy, Monoclonal,Monoclonal Gammopathies,Paraimmunoglobulinemia,Paraimmunoglobulinemias,Paraproteinemia,Plasma Cell Dyscrasias,Monoclonal Gammapathies,Monoclonal Gammopathy,Cell Dyscrasia, Plasma,Dyscrasia, Plasma Cell,Monoclonal Gammapathy,Plasma Cell Dyscrasia
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D016030 Kidney Transplantation The transference of a kidney from one human or animal to another. Grafting, Kidney,Renal Transplantation,Transplantation, Kidney,Transplantation, Renal,Kidney Grafting,Kidney Transplantations,Renal Transplantations,Transplantations, Kidney,Transplantations, Renal

Related Publications

J Radl, and R M Valentijn, and J J Haaijman, and L C Paul
June 2023, International journal of molecular sciences,
J Radl, and R M Valentijn, and J J Haaijman, and L C Paul
August 1995, Casopis lekaru ceskych,
J Radl, and R M Valentijn, and J J Haaijman, and L C Paul
January 2005, Journal of nephrology,
J Radl, and R M Valentijn, and J J Haaijman, and L C Paul
December 1997, Journal of the International Federation of Clinical Chemistry,
J Radl, and R M Valentijn, and J J Haaijman, and L C Paul
February 2014, Drugs & aging,
J Radl, and R M Valentijn, and J J Haaijman, and L C Paul
February 1991, Journal of clinical & laboratory immunology,
J Radl, and R M Valentijn, and J J Haaijman, and L C Paul
October 1977, Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,
J Radl, and R M Valentijn, and J J Haaijman, and L C Paul
September 2005, Minerva urologica e nefrologica = The Italian journal of urology and nephrology,
J Radl, and R M Valentijn, and J J Haaijman, and L C Paul
January 1975, Minerva chirurgica,
J Radl, and R M Valentijn, and J J Haaijman, and L C Paul
August 1991, Clinical immunology and immunopathology,
Copied contents to your clipboard!